Por: RTTNews Health November 25, 2022
Spectrum Pharmaceuticals Inc.'s () Poziotinib, proposed for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer harboring HER2 exon 20 insertion mutations, has been denied as expected. In September, the FDA Oncologic Drugs Advisory Committee had voted 9 - 4 concluding that the benefits of Poziotinib do not outweigh risks despite clear unmet need. Following the disappointing... + full article
MarketWatch USA Business October 15, 2022
Last month, the DOJ sued to block the deal, alleging that the merger would eliminate head-to-head competition between Assa Abloy and Spectrum, risking higher prices, lower quality, reduced innovation and poorer service in the sale of at least two types of residential door... + más
The Justice Department Needs to Get Out of Its Own Way in the Trump Investigations | The Daily Beast
Supreme Court Rules Against Trump On Mar-A-Lago Classified Documents | Forbes
ABC News USA Health September 30, 2022
WASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.Amylyx Pharmaceuticals said the Food and... + más
Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post
ALS drug wins FDA approval despite questionable data | WPLG Local 10
WPLG Local 10 USA Politics September 30, 2022
WASHINGTON – A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.The Food and Drug Administration approved... + más
ALS drug wins FDA approval despite questionable data | ABC News
Associated Press USA Science September 30, 2022
WASHINGTON (AP) — A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.The Food and Drug Administration... + más
WPLG Local 10 USA Health September 24, 2022
WASHINGTON – The Food and Drug Administration acknowledged Tuesday that its response to the U.S. was slowed by delays in processing a whistleblower complaint and test samples from the nation’s largest formula factory.A 10-page report from the agency offers its first formal... + más
FDA concedes delays in response to baby formula shortage | ABC News
‘If the FDA is expected to do more, it needs more’: FDA investigation into baby-formula crisis points to its own shortcomings. But shortages persist. | MarketWatch
ABC News USA Health September 21, 2022
WASHINGTON -- The Food and Drug Administration acknowledged Tuesday that its response to the U.S. infant formula shortage was slowed by delays in processing a whistleblower complaint and test samples from the nation’s largest formula factory.A 10-page report from the agency... + más
FDA concedes delays in response to baby formula shortage | Associated Press
Internal FDA report on infant formula crisis details shortfalls in response | ABC News
Associated Press USA Politics September 21, 2022
WASHINGTON (AP) — The Food and Drug Administration acknowledged Tuesday that its response to the U.S. was slowed by delays in processing a whistleblower complaint and test samples from the nation’s largest formula factory.A 10-page report from the agency offers its first... + más
About iurex | Privacy Policy | Disclaimer |